Blog
Get the latest news about liver diseases and more
Get the latest news about liver diseases and more
GLP-1 weight-loss drugs offer significant benefits but may pose risks, including potential eating disorders and anorexia nervosa in genetically or psychologically predisposed individuals.
Viral load and transaminase levels are important indicators for assessing the prognosis of chronic hepatitis B. A study published in The Lancet found that an HBV DNA level above 2,000 IU/mL and elevated transaminases are associated with a higher risk of advanced liver disease. These markers can help guide patient monitoring and individualized treatment decisions.
Physical activity plays an essential role in preventing and treating fatty liver disease by reducing liver fat accumulation and inflammation. Both aerobic and resistance exercise offer benefits for liver health. Regular exercise, including 150 to 300 minutes of moderate-intensity activity per week, can support liver health and overall well-being.
A study published in Scientific Reports investigated the relationship between periodontitis and fatty liver disease. The findings show that signs of periodontal disease, including a periodontal pocket depth greater than 6 mm and gingival bleeding, are associated with fatty liver disease and a greater degree of liver fibrosis.
Vitamin D plays an important role in fatty liver disease, including in patients with normal body weight. Recent research suggests that maintaining adequate vitamin D levels may improve liver health and metabolic parameters in affected individuals.
Elafibranor is a newly approved treatment for patients with primary biliary cholangitis (PBC) who do not respond adequately to ursodeoxycholic acid. Clinical studies show improved liver function and establish it as a promising therapeutic option.
A study published in The New England Journal of Medicine shows that Bepirovirsen significantly increases the likelihood of achieving a functional cure for chronic hepatitis B.
Fatty liver and hepatitis B can coexist and worsen liver damage. Combined treatment helps reduce inflammation, fibrosis, and disease progression.
23 de August de 2018
2 de June de 2020
20 de May de 2022
Hepatitis A is an acute inflammatory disease of the liver, caused by infection with hepatitis A virus (VAH).
It is a viral infection of the liver that causes inflammation of the liver and the death of hepatocytes.
It is a progressive chronic inflammatory disease of the liver that can lead to liver cirrhosis.
Hepatitis is an inflammation of the liver, and in the case of hepatitis C, caused by infection with hepatitis C virus (HCV)
Up to 30% of patients with cryptogenic hepatitis can be caused by the seronegative hidden infection by hepatitis C virus (HIC).
It is a chronic progressive liver disease that mainly affects women (90% of cases) from the fourth decade of life.